MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities

SIMPLE SUMMARY: Secondary amplifications/copy number changes of the gene MET (MET protocol oncogene) play a significant role in the development of resistance to targeted drugs in advanced non-small cell lung cancer (NSCLC). In this review, we aim to clarify the biological mechanisms of MET amplifica...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Kang, Hong, Lingzhi, Zhang, Jianjun, Le, Xiuning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913224/
https://www.ncbi.nlm.nih.gov/pubmed/36765572
http://dx.doi.org/10.3390/cancers15030612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913224/
https://www.ncbi.nlm.nih.gov/pubmed/36765572
http://dx.doi.org/10.3390/cancers15030612

Ejemplares similares